Infliximab (Remsima® SC). HTA ID: 20042

Assessment Status Rapid Review Complete
HTA ID 20042
Drug Infliximab
Brand Remsima® SC
Indication For treatment of adult patients with Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis in line with the adult indications of the IV formulation.
Assessment Process
Rapid review commissioned 23/09/2020
Rapid review completed 15/10/2020
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Remsima SC not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations March 2022.